Home › Therapeutic areas › Hematology › Sickle Cell Disease
Sickle Cell Disease (4 companies)
Companies with an active program in Sickle Cell Disease.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals | HematologyMetabolic Rare | 1 | Approved | $1.76B | 7 |
| BEAM | Beam Therapeutics | HematologyMetabolic+1 Rare | 1 | Phase 2 | $2.73B | 6 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 1 | Phase 3 | $3.59B | 9 |
| VTVT | vTv Therapeutics | HematologyMetabolic+1 Rare | 1 | Phase 3 | $84.4M | 9 |
No companies match.